Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 17/20 | 0.53 |
| ▸ | PIM3 | Q86V86 | 16/20 | 0.53 |
| ▸ | PIM2 | Q9P1W9 | 15/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.34 |
| ▸ | HTR3B | O95264 | 2/20 | 0.34 |
| ▸ | HTR3A | P46098 | 2/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.34 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15854652 | 0.91 | PIM1 (0.65) | PIM1PIM3PIM2 | |
| SCHEMBL15854667 | 0.79 | PIM1 (0.45) | PIM1PIM3PIM2 | |
| SCHEMBL15854638 | 0.77 | PIM1 (0.51) | PIM1PIM3PIM2KDM4EMEN1 | |
| SCHEMBL15854657 | 0.76 | PIM1 (0.63) | PIM1PIM3PIM2 | |
| SCHEMBL15854653 | 0.75 | PIM1 (0.64) | PIM1PIM3PIM2 | |
| SCHEMBL15854660 | 0.74 | GUSB (0.38) | PIM1PIM3PIM2KDM4E | |
| SCHEMBL12616297 | 0.73 | PIM1 (0.52) | PIM1PIM3PIM2 | |
| SCHEMBL15854687 | 0.72 | PIM1 (0.41) | PIM1PIM3PIM2 | |
| SCHEMBL15854650 | 0.72 | PIM1 (0.38) | PIM1PIM3PIM2 | |
| SCHEMBL15854692 | 0.71 | PIM1 (0.37) | PIM1PIM3PIM2KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321756-B2 | Azole compounds as PIM inhibitors | AMGEN INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | AMGEM INC. (US) | 2014-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | PIM1, PIM3, PIM2 | PIM1 1/4885PIM3 2/4885PIM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.